Journal of Cutaneous Immunology and Allergy最新文献

{"title":"Changes in patient-perceived aggravating factors during the course of atopic dermatitis","authors":"Nozomi Yanagida MD,&nbsp;Ryo Saito MD, PhD,&nbsp;Akiko Kamegashira MD, PhD,&nbsp;Satoshi Morioke MD, PhD,&nbsp;Akio Tanaka MD, PhD","doi":"10.1002/cia2.12329","DOIUrl":"10.1002/cia2.12329","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to clarify how patient-perceived aggravating factors change during the course of AD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study involved a questionnaire-based survey administered to 115 patients with AD at our hospital. The changes in patient-perceived aggravating factors were examined as treatment progressed by readministering the questionnaire to 36 patients 6 months later.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The most frequent aggravating factors at the first visit were sweating, emotional stress, and house dust. The number of patients who identified food, dust mites, house dust, pollen, and pets as aggravating factors decreased during the course of the disease. However, the number of patients who identified sweating, environmental factors, emotional stress, and lack of sleep as aggravating factors did not differ from those at the first visit; this included those who newly identified these as aggravating factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Many patients with AD are concerned about the aggravating factors, and it may be possible to reduce aggravating factor-related anxiety by informing patients that certain aggravating factors may change during treatment. Hence, it is necessary to ask patients about the aggravating factors at the first visit and fixed intervals and resolve them immediately.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12329","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135244619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brentuximab vedotin treatment for mycosis fungoides with CD30+ large-cell transformation in the early stage","authors":"Shujiro Hayashi MD, PhD,&nbsp;Shown Tokoro MD,&nbsp;Ken Igawa MD, PhD","doi":"10.1002/cia2.12330","DOIUrl":"10.1002/cia2.12330","url":null,"abstract":"<p>Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, is characterized by the proliferation of small- to medium-sized atypical, usually CD4+ T cells in the skin.<span>¹</span> Mycosis fungoides with large-cell transformation (LCT) is an aggressive subtype defined by the presence of large cells comprising &gt;25% of the lesion infiltrate or the presence of microscopic nodules of large cells. Large-cell transformation occurs in 20%–55% of advanced MF cases and is often a histological marker of poor prognosis and is associated with a mean 5-year survival rate of &lt;20%.<span>¹</span> Herein, we present a patient with MF-LCT in its early stage that was successfully treated with brentuximab vedotin (BV), an anti-CD30 antibody.</p><p>A woman in her early 30s had erythema with pruritus and pigmentation on her trunk and thighs for 3 years (Figure 1A). Following subsequent histopathological diagnosis as MF (negative CD30+ lymphocytes at this time), she was successfully treated with topical steroids and ultraviolet therapy and showed no progression for approximately 10 years. In her early 40s, the rash slowly expanded and was treated with bexarotene (450–150 mg/day). One year later, the eruption intensified, with erythema observed on 40% of the body and multiple skin tumors of ≥1 cm (Figure 1B,C). Histopathology and immunohistochemistry of the tumors confirmed infiltration with CD3+, CD4+, CD5+, CD8+ (CD4/CD8: 10/1), CD30+, and CD20− lymphocytes, and CD30+ lymphocytes with large nuclei comprised 30% of the infiltrate (Figure 1D,E). The patient's complete blood count was normal, and the peripheral blood smear was negative for Sézary cells. Bone marrow examination showed no infiltration of atypical lymphocytes. No lymph node metastasis was found on positron emission tomography–computed tomography. Mycosis fungoides stage IIB (T3M0N0) with CD30+ LCT was diagnosed, and BV treatment was initiated instead of bexarotene. After three doses, the eruption area decreased, and the nodules became flattened (Figure 1E,F). After a total of 16 BV treatments, the only side effect observed was mild sensory polyneuropathy.</p><p>Brentuximab vedotin is an antibody–drug conjugate (ADC) in which monomethyl auristatin E (MMAE), which has cytotoxic activity, and an anti-CD30 IgG1-type chimeric antibody are linked via a protease-cleavable linker. The ADC inhibits tumor growth by first binding to CD30+ cells. Then, after being taken up into the cells as an ADC–CD30 complex, it releases MMAE through a proteolytic reaction. The free MMAE further inhibits microtubule formation and induces cell cycle arrest and apoptosis.<span>²</span> In a clinical trial of 30 patients (MF and Sézary syndrome), the response rate for BV was 70%, wherein 54% of the respondents were free of disease progression for 1 year<span>³</span>; however, the information on MF-LCT is still limited.</p><p>Bhari N et al. reported that the survival p","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12330","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135246702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergic contact dermatitis caused by Dermabond® Advanced: The role of temperature as a potential risk factor","authors":"Mai Hasegawa MD,&nbsp;Takasuke Ogawa MD,&nbsp;Yumi Ogawa MD,&nbsp;Shigaku Ikeda PhD","doi":"10.1002/cia2.12328","DOIUrl":"10.1002/cia2.12328","url":null,"abstract":"<p>We herein report a case of allergic contact dermatitis (ACD) caused by Dermabond® Advanced, which was diagnosed by a patch test using SurgiSeal® (Nitcho Kogyo, Tokyo, Japan) as a control. A difference in the temperature increase at the time of application suggested that temperature may be a risk factor for sensitization.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12328","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135719660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two cases of acute-onset cystoid macular edema and serous retinal detachment associated with combined use of encorafenib and binimetinib for advanced melanoma: A possible confounding risk for drug intolerance","authors":"Takumi Hasegawa MD,&nbsp;Shiro Iino MD, PhD,&nbsp;Misako Fujisaki MD,&nbsp;Sayuri Okamura MD,&nbsp;Natsuki Baba MD, PhD,&nbsp;Nami Tanaka MD,&nbsp;Yuko Takeuchi MD,&nbsp;Noritaka Oyama MD, PhD,&nbsp;Minoru Hasegawa MD, PhD","doi":"10.1002/cia2.12325","DOIUrl":"10.1002/cia2.12325","url":null,"abstract":"<p>While combined use of BRAF/MEK inhibitors has elicited dramatic clinical efficacy in incurable melanoma, drug-associated retinopathy has become an emerging adverse event. We present two Japanese men with advanced melanoma who developed visual impairment due to serous retinal detachments (SRDs) with cystoid macular edema (CME) immediately after initial administration of encorafenib/binimetinib, a BRAF and MEK inhibitor. One case had drug-intolerable retinopathy on repeat dosing. Both cases were switched to another BRAF/MEK inhibitors, dabrafenib/trametinib, with no recurrence of SRDs. Co-existing CME may be a confounding risk for the early development of SRDs with encorafenib/binimetinib therapy, providing attention during drug administration.</p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12325","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136310933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of methotrexate-related lymphoproliferative disorder resolved with discontinuation of the drug: A literature review for clinical characteristics in 105 Japanese cases","authors":"Shintaro Higashida MD,&nbsp;Erina Kodaka MD,&nbsp;Hiromichi Iwasaki MD, PhD,&nbsp;Hideaki Sakai MD,&nbsp;Noritaka Oyama MD, PhD,&nbsp;Minoru Hasegawa MD, PhD","doi":"10.1002/cia2.12324","DOIUrl":"10.1002/cia2.12324","url":null,"abstract":"<p>We report a case of rheumatoid arthritis who developed cutaneous diffuse large B-cell lymphoma during methotrexate (MTX) monotherapy with prompt resolution after discontinuation of the drug. Our literature review of over 100 reported Japanese cases revisited the potential risk of treatment resistance and/or repeated recurrence of lymphomas, particularly in cases that were unresponsive to the withdrawal of MTX or received a higher cumulative dose.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12324","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135938589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stevens-Johnson syndrome without skin lesions extensively involving the digestive tract","authors":"Yuto Ishikawa MD,&nbsp;Sayaka Ajima MD,&nbsp;Hideo Hashizume MD, PhD","doi":"10.1002/cia2.12323","DOIUrl":"10.1002/cia2.12323","url":null,"abstract":"<p>We have experienced a case of SWSL involving significant gastrointestinal erosion that occurred after TMP-SMX medication. For accurate diagnosis and prompt treatment of complications, it is essential to be aware of the possibility of this phenomenon.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12323","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48911943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased epidermal AXL expression and increased infiltration of AXL-expressing dendritic cells in psoriasis","authors":"Yukiko Ito MD,&nbsp;Sayaka Shibata MD, PhD,&nbsp;Asumi Koyama MD,&nbsp;Lixin Li MD,&nbsp;Eiki Sugimoto MD,&nbsp;Haruka Taira MD,&nbsp;Yuka Mizuno MD,&nbsp;Kentaro Awaji MD, PhD,&nbsp;Shinichi Sato MD, PhD","doi":"10.1002/cia2.12319","DOIUrl":"10.1002/cia2.12319","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Psoriasis is a chronic skin inflammatory disease characterized by epidermal proliferation and inflammatory cell infiltration. AXL is a tyrosine kinase receptor that promotes cell proliferation and invasion in cancer cells, and its expression is elevated in multiple tumors. However, less is known about its expression and function in inflammatory diseases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The aim of this study is to examine AXL expression in psoriasis and investigate the biological function of AXL under psoriatic conditions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>AXL mRNA expression was decreased in psoriatic skin compared to healthy skin, and an inverse correlation with neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio was observed. Immunohistochemical staining of psoriatic skin revealed decreased AXL expression of the epidermis and an increased number of AXL-positive dendritic cells in the dermis. Stimulation of epidermal keratinocytes with antimicrobial peptide LL37, but not with IL-17A, resulted in decreased AXL expression. Knockdown of AXL in epidermal keratinocytes did not affect cell proliferation or expression of psoriasis-associated cytokines and chemokines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Decreased epidermal AXL expression and increased infiltration of AXL-expressing dendritic cells were revealed in psoriasis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12319","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48617135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Normocomplementemic urticarial vasculitis with laryngeal and intestinal tract edema","authors":"Daisuke Kawakami MD,&nbsp;Yoshiko Oda MD, PhD,&nbsp;Yumi Oka MD,&nbsp;Anri Morita MD,&nbsp;Keiko Kuroda MD,&nbsp;Yoji Hirai MD, PhD,&nbsp;Chikako Nishigori MD, PhD,&nbsp;Atsushi Fukunaga MD, PhD","doi":"10.1002/cia2.12312","DOIUrl":"10.1002/cia2.12312","url":null,"abstract":"<p>An 81-year-old Japanese man presented with a history of recurrent eyelid swelling and purpura on the face, neck, and limbs. Because the initial clinical presentation was angioedema alone, the patient was treated with an H1-receptor antagonist and tranexamic acid as for an idiopathic angioedema. The patient also experienced dyspnea simultaneously with edema on the face and limbs and was thus taken to the emergency room, where laryngeal edema was confirmed on laryngeal fiber. A good response to hydrocortisone injection was observed in the patient. ACE inhibitors were never prescribed for the patient, and there was no family history of angioedema. Laboratory data indicated normocomplementemia, and skin biopsies revealed leukocytoclastic vasculitis. Therefore, the patient was diagnosed with NUV. Following hospitalization, the patient experienced appetite loss and the CRP level increased, presenting with thickening and stranding around colon tissues on abdominal CT. These symptoms responded well to prednisone treatment. Given that the initial clinical manifestation of the current case was mainly angioedema, physicians should consider that angioedema may in rare cases be diagnostic for UV.</p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12312","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42427882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of disseminated erythematous drug eruption caused by favipiravir in a patient with COVID-19","authors":"Aki Honda MD,&nbsp;Toshiyuki Yamamoto MD, PhD","doi":"10.1002/cia2.12321","DOIUrl":"10.1002/cia2.12321","url":null,"abstract":"<p>The case of a widespread erythematous drug eruption brought on by favipiravir is described here. Patch tests and the drug lymphocyte transformation test (LTT) both indicated a positive reaction. Since COVID-19 patients take many medications, the potential for a drug eruption must be taken into account when diagnosing a rash.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12321","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42624162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The utility of IL36RN mutation analysis in an elderly patient with generalized pustular psoriasis patient treated with secukinumab","authors":"Satoko Minakawa MD, PhD,&nbsp;Yasushi Matsuzaki MD, PhD,&nbsp;Soichiro Watanabe MD, PhD,&nbsp;Kazumitsu Sugiura MD, PhD,&nbsp;Daisuke Sawamura MD, PhD","doi":"10.1002/cia2.12318","DOIUrl":"10.1002/cia2.12318","url":null,"abstract":"<p>We present a case of Generalized pustular psoriasis (GPP) presented with SARS-CoV-2 infection under the control of secukinumab. Mutation analysis revealed a heterogeneous c.28C&gt;T (p.Arg10X) mutation in IL36RN. Mutation analysis should be considered to enable preparation for biologic therapy to treat intractable flare-ups.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12318","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44872302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}